Contact Pharma: Preclinical Perspectives- Providers look to a brighter future

Jun 01 2012

Providers look to a brighter future
Contract Pharma

Earlier in the drug development process, providers are finally seeing an uptick in sponsor demand for specialized services, after paring away at excess capacity and trying to right-size preclinical operations.  

Read what Nancy Gillett, corporate executive vice president and chief scientific officer at Charles River Laboratories, and other experts have commented on keeping up with this increased demand for services such as biomarkers, biosimilars, orphan drugs, as well as certain therapeutic areas.

Click here to read the full article from Contract Pharma.